Large Volume Wearable Injectors - 2nd Edition

News provided by

Sep 23, 2014, 10:59 ET

DUBLIN, September 23, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/v9xss8/large_volume) has announced the addition of the "Large Volume Wearable Injectors - 2nd Edition" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the market has come a long way. The rising prevalence of chronic diseases is one of the key factors driving the companies to develop systems that allow patients to self-administer drugs. Taking the concept of self-injectors to a new stratum, Large volume Wearable Injectors' have surfaced recently. Also known as bolus injectors and non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.

One of the main drivers for the perceived growth of these injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Some customized drug-device combinations are currently being developed for specific drugs such as Herceptin, AMG-145 and Furosemide. In addition, pharma companies have many undisclosed programs which are likely to provide the necessary growth impetus in the near future.

This development is being led jointly by established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, SteadyMed Therapeutics, Ratio Drug Delivery, Sensile Medical, Enable Injections and scPharmaceuticals. It is widely anticipated that, once ready, such devices which will allow self-administration of high viscosity, large volume biologics and be readily adopted in the industry.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. OVERVIEW AND MARKET BACKGROUND

5. TARGET DRUGS FOR LARGE VOLUME WEARABLE INJECTORS

6. CASE STUDIES

7. PRODUCT PROFILES

8. MARKET SIZE AND FORECAST

9. SWOT ANALYSIS

10. COMPANY PROFILES

11. INTERVIEW TRANSCRIPTS

12. CONCLUSION

13. APPENDIX 1: Tabulated Data

14. APPENDIX 2: List of Companies and Organizations

Companies Mentioned: